GLAXF - GlaxoSmithKline plc
Other OTC - Other OTC Delayed price. Currency in USD
Show:
Annual
Income statement
Currency in GBP. All numbers in thousandsBreakdown
ttm
31/12/2019
31/12/2018
31/12/2017
31/12/2016
Total revenue
35,183,000
33,754,000
30,821,000
30,186,000
27,889,000
Cost of revenue
12,329,000
11,863,000
10,241,000
10,342,000
9,290,000
Gross profit
22,854,000
21,891,000
20,580,000
19,844,000
18,599,000
Operating expenses
Research development
4,749,000
4,568,000
3,893,000
4,476,000
3,628,000
Selling general and administrative
11,841,000
11,402,000
9,915,000
9,672,000
9,366,000
Total operating expenses
15,976,000
15,599,000
13,516,000
13,783,000
12,573,000
Operating income or loss
6,878,000
6,292,000
7,064,000
6,061,000
6,026,000
Interest expense
876,000
871,000
718,000
698,000
671,000
Income before tax
6,761,000
6,221,000
4,800,000
3,525,000
1,939,000
Income tax expense
799,000
953,000
754,000
1,356,000
877,000
Income from continuing operations
5,962,000
5,268,000
4,046,000
2,169,000
1,062,000
Net income
5,380,000
4,645,000
3,623,000
1,532,000
912,000
Net income available to common shareholders
5,380,000
4,645,000
3,623,000
1,532,000
912,000
Basic EPS
-
0.94
0.74
0.31
0.19
Diluted EPS
-
0.93
0.73
0.31
0.19
Basic average shares
-
4,947,000
4,914,000
4,886,000
4,860,000
Diluted average shares
-
5,016,000
4,971,000
4,941,000
4,909,000
EBITDA
-
9,426,000
7,374,000
6,145,000
4,384,000
© 2020 Verizon Media. All rights reserved.